Contact us
Please enter your contact details and the Mindpeak team will be in touch.
Book a Demo
Select a date and slot that works for you.
FAQ
Essential definitions for AI, pathology, and regulatory frameworks
No. PhenoScout AI is For Research Use Only and not for use in diagnostic procedures. Every image carries a full audit trail, and Mindpeak's quality management system is certified to ISO 13485. Mindpeak's CE-IVD diagnostic products are a separate line.
Images arrive directly from ZEISS Axioscan 7 Spatial Biology through SlideStream, and from other platforms through Mindpeak EasyUpload. Results open in the PhenoScout AI viewer, and result reports export as .xlsx files, ready to attach to records in your LIMS.
PhenoScout AI is cloud-native and runs in the browser. For teams whose images and results must stay inside their own network, an on-premise deployment (Docker, in-network) is available on request.
Two mIF models: mIF-membrane for membrane and cytoplasmic markers such as HER2, CD8, panCK and CD68, and mIF-nucleus for nuclear markers such as Ki-67 and FOXP3. Brightfield IHC-membrane and IHC-nucleus models are included in every package. All are built on peakFrontier, and the mIF models are trained on 40+ immune and cancer biomarkers. Mindpeak's CE-IVD diagnostic algorithms are purchased separately.
No. The models are pre-trained, so there is no pipeline to build and no algorithm to tune. You define phenotypes by marker logic in the viewer, without scripting.
Multiplex immunofluorescence, including cyclic stainings of 40+ channels: ZEISS Axioscan 7 Spatial Biology (CZI), RareCyte Orion (OME-TIFF), Akoya PhenoImager HT (QPTIFF or OME-TIFF) and Lunaphore COMET (OME-TIFF). Brightfield IHC models are included in every package, and H&E slides scan and upload through the same workflow. Further modalities are planned.
Just a web browser. peakAcademy is browser-based with global 24/7 access, and conference mode is mobile- and touchscreen-optimized with no login required.
A CME certification submission is ongoing and currently planned for 2027.
Participants receive auto-generated certificates on completion and can log back in anytime to revisit their cases.
Yes. You can add sponsor logos, study disclaimers, and regulatory footers at the page level, and structure multi-stage courses with cohort control and timed unlock order.
Every case is scored against verified ground truth. Trainers see live completion dashboards and case-level metrics - percent correct, accuracy, sensitivity, and concordance vs. truth - all exportable as PDF or data for post-training review, remediation, or publication support.
Yes. You can supply your own dataset, or have Mindpeak source a custom dataset from a global network of reference centers. Mindpeak experts help plan the ideal setup for your training.
peakAcademy draws on Mindpeak's AI portfolio across solid tumor types and indications such as lung, breast, and gastric, covering biomarkers including PD-L1, HER2, TROP2, CLDN18.2, ER/PR, Ki-67, DLL3, among others. Contact us to discuss a specific target.
Mindpeak focuses on scalable Frontier Model AI built for real-world deployment in regulated environments. Our emphasis is on validation, reproducibility and long-term integration rather than experimental or isolated tools.
Mindpeak prioritizes diverse data curation, cross-site validation and continuous monitoring to support responsible and generalisable AI deployment across clinical environments.
Mindpeak supports secure deployment models and complies with industry-standard data protection and IT security requirements
Mindpeak integrates with established digital pathology infrastructures and supports scalable deployment across laboratory networks and pharmaceutical partnerships.
No. Mindpeak software integrates into established digital pathology systems without disrupting routine clinical practice.
peakFrontier operates across multiplex immunofluorescence, immunohistochemistry and H&E, enabling consistent analysis across discovery, translational research and clinical development workflows.
Mindpeak develops applied AI solutions for digital pathology and precision medicine. Our technology strengthens reproducibility and confidence in tissue-based biomarker assessment across clinical diagnostics and pharmaceutical drug development.
peakFrontier is Mindpeak’s foundational AI architecture. It analyses digital pathology images, including multiplex immunofluorescence, immunohistochemistry and H&E, and converts complex tissue information into structured, quantitative outputs suitable for regulated clinical and research use.
Mindpeak’s peakFrontier AI architecture powers a portfolio of specialised applications designed for clinical and pharmaceutical use:
- peakDiscover – Extracts tissue and cellular features to characterise the tumour microenvironment and identify biomarker signatures
- peakDeploy – Enables scalable deployment of AI tissue biomarker solutions across laboratory networks
- peakAcademy – An AI-native training platform supporting standardised, reproducible biomarker assessment
- peakPredict – A predictive AI ecosystem designed to support the analysis of tissue-based features in relation to treatment response and clinical outcomes
Each solution draws from the same validated underlying architecture, ensuring consistency across discovery, development and clinical implementation.
No. Mindpeak’s AI is designed to support pathologists, not replace them. Our systems function as clinical decision support tools and act as added insurance in complex or high-volume environments. Final diagnostic responsibility remains with the clinician.
Yes. Mindpeak offers CE-IVD certified diagnostic products and operates under an ISO 13485 certified quality management system.
Depending on the product and region, Mindpeak solutions are available as research use only or as CE-IVD certified diagnostic tools. Regulatory status is clearly defined for each product.
Mindpeak solutions undergo structured validation prior to deployment and are evaluated across multiple clinical sites. Performance is continuously monitored in real-world environments to ensure reliability and reproducibility.
Mindpeak operates within regulated clinical environments and maintains a formal quality management system. Governance, documentation and post-deployment monitoring are integral to our approach to AI in healthcare.
Mindpeak’s AI supports quantitative biomarker assessment, companion diagnostic algorithm development and reproducible analysis across multi-site clinical trials. By reducing variability in tissue-based assessment, our technology strengthens confidence in patient stratification and endpoint evaluation.
Our AI applies consistent quantitative analysis across laboratories and clinical sites, helping to reduce inter-observer variability and standardise biomarker interpretation in global studies.